I'm a 15-year-old sophomore starting on Varsity as a OLB and RB. 5'9" 160 4.68 verified 40. 20 mph 25" Vertical 2028 graduate @CoachMachadojr @Rude_WUBearcats @Coach_Needham67 @CoachAllshouse @coachboom_acu @jfederico8 @coach_ksuttles @KelleyBeMoore @DonnyMooreJr @CoachRLaurel @coacholney @WYLIE_NMHU @CoachBeauGrech @CoachGallasASU @CoachGreenie @athletics_r @ArizonaFBall @5StarFBRecruits @JacobScottDavis @CoachMcGrath22 @JaxWarshawUA @CoachSanders14 @coachcgibbs @Scott_Orders @jwesleyg1228 @JamesSkalski @CoachJG_ @CoachJRut @Jeremey_FSU @CoachMcNamara9 @ethompson40 @CoachHutzler @Coach_NMathews @licostie_nick5 @CoachUno1 @_CoachKThompson @coach_tko @ReggieBuchanan @CoachBull16 @FLCCoach_Grinde @CoachB_Larson @gridironarizona @PrepRedzoneAZ @TopPreps @lottsjeston #GloryToGod# #StudentAthlete# #RecruitMe#

I'm a 15-year-old sophomore starting on Varsity as a OLB and RB. 5'9" 160 4.68 verified 40. 20 mph 25" Vertical 2028 graduate @CoachMachadojr @Rude_WUBearcats @Coach_Needham67 @CoachAllshouse @coachboom_acu @jfederico8 @coach_ksuttles @KelleyBeMoore @DonnyMooreJr @CoachRLaurel @coacholney @WYLIE_NMHU @CoachBeauGrech @CoachGallasASU @CoachGreenie @athletics_r @ArizonaFBall @5StarFBRecruits @JacobScottDavis @CoachMcGrath22 @JaxWarshawUA @CoachSanders14 @coachcgibbs @Scott_Orders @jwesleyg1228 @JamesSkalski @CoachJG_ @CoachJRut @Jeremey_FSU @CoachMcNamara9 @ethompson40 @CoachHutzler @Coach_NMathews @licostie_nick5 @CoachUno1 @_CoachKThompson @coach_tko @ReggieBuchanan @CoachBull16 @FLCCoach_Grinde @CoachB_Larson @gridironarizona @PrepRedzoneAZ @TopPreps @lottsjeston #GloryToGod# #StudentAthlete# #RecruitMe#

I'm a cardiologist. For 25 years I've been trained to be brilliant at the worst moment of your life. The 3am cath lab. The stent threaded into a closing artery. The bypass. The shock that restarts a heart that had already quit. I've stood in those rooms more times than I can count, and I will never stop being in awe of what we can do there. But I need to tell you the quiet secret of my entire field: By the time you meet me in that room, the disease has already won most of the war. We are firefighters who show up after the house is halfway gone. We've built the most sophisticated rescue system in the history of medicine — and aimed almost none of it at stopping the fire from starting. 800,000 Americans still have a heart attack every year. A staggering share of them were preventable — not weeks earlier, but years earlier. We just had no way to see it coming. That is now changing, and the shift is so profound that ACC President @Drroxmehran and @EricTopol just laid it out as a once-in-a-generation turning point for medicine — a call to move cardiology from reacting to disease to predicting and preventing it before it ever declares itself. Here is what almost no one outside my field understands yet. Point by point. We've been staring at the wrong thing for decades. Old cardiology was obsessed with the narrowing — how clogged is the pipe on the angiogram. But here's the twist that still surprises even doctors: most heart attacks don't come from the tight, obvious blockage. They come from softer, "invisible" plaque that isn't blocking much of anything — until the day it ruptures without warning. We were reading the visible enemy and missing the one that actually kills. The real villains are inflamed, unstable plaque and the fire smoldering in the artery wall. We can now see that hidden fire. AI-powered CT scans of the heart can detect the dangerous features older imaging missed — the composition of a plaque, and the inflammation glowing in the fat around the vessel, years before anything ruptures. We are no longer guessing which plaque is a ticking clock. We're starting to read the clock directly. Your DNA can flag the danger before you have a single symptom. Polygenic risk scores add up thousands of tiny genetic variants into one number. They can identify people carrying 2 to 7 times the lifetime risk — people with normal cholesterol, no family history, no warning signs at all. A young, "healthy" 30-year-old could be walking around with a hidden inheritance we can finally catch and act on decades early. A photograph of your eye can predict your heart. This is the one that stops people cold. Deep-learning models can look at an ordinary retinal photo — the kind snapped at the optometrist — and estimate your biological age and your future heart-attack risk. The back of your eye is the only place in the entire body where we can see living blood vessels with the naked eye. It turns out they've been narrating your cardiovascular story the whole time, and we finally learned to read the language. And now the machines that tie it all together. Multimodal AI can fuse your genetics, your imaging, your medical record, and the data streaming off your watch into a single forecast of where your heart is headed — a living risk trajectory that updates in real time. Pair that with a new generation of drugs that crush the most dangerous cholesterol particles, cool inflammation, and protect the heart independent of weight — and primary prevention becomes something we've never had before: precise. Put all five together and something historic becomes possible: We can identify the person who is going to have a heart attack in 2045 — today. And we can rewrite that ending. Here's why this matters more than almost anything else in medicine. Of the great age-related killers — cancer, dementia, heart disease — heart disease is the most preventable. We already have the lifestyle levers. We already have medications that work. Statins alone cut the risk of a major cardiac event by roughly 20–25% for each substantial drop in LDL, and we've held that power for years. What we lacked was knowing exactly who to protect, and when to begin. Now we're being handed the map. Picture it: a routine checkup — or even an eye exam — quietly generating a risk profile that says this person needs us now, not in thirty years. That is not science fiction. Every single piece already exists and is maturing fast. I became a cardiologist to save lives. And I'm realizing the most powerful version of that was never the dramatic rescue at midnight. It's the heart attack that never happens. The room you never end up in. The ordinary Tuesday, twenty years from now, that you simply get to keep — never knowing how close you came to losing it. The tools are finally here. Our only job now is the courage to use them early — to stop waiting for the body to break before we're willing to care for it. The future of the heart isn't a better rescue. It's a life that never needed rescuing.

I'm a cardiologist. Today the FDA approved something I've been waiting two decades for: the first oral PCSK9 inhibitor in history. A once-daily pill — Lipfendra (enlicitide), from Merck — that lowers LDL as powerfully as the injections we've relied on. This is one of those days that quietly changes the trajectory of the disease that kills more people than anything else on earth. Let me tell you exactly why — and who should act on it this week. Start with the biology, because it's elegant. Your liver cells are covered in LDL receptors — molecular catcher's mitts that grab "bad" cholesterol out of your blood and pull it in for disposal. The more receptors you have working, the lower your LDL. But your body makes a protein called PCSK9 whose entire job is to find those receptors and drag them to the incinerator before they can be reused. PCSK9 is the saboteur. Block PCSK9, and the receptors survive. They get recycled back to the surface. They keep clearing LDL, over and over. Cholesterol plummets. It is one of the most powerful mechanisms we have ever discovered in cardiology. And until today, you could only access it through a needle. That needle was a bigger problem than most people realize. The injectables — Repatha, Praluent — are phenomenal drugs. But needle aversion, injection-site reactions, pharmacy logistics, and cost meant that millions of patients who desperately needed them simply said no. I have watched patients stay at heart-attack-level cholesterol for years because they wouldn't inject. The barrier was never the science. It was human. Now the trial data — from a program spanning over 19,000 participants — and it's genuinely impressive. Roughly 60% LDL reduction. A placebo-adjusted 56% in the main lipids trial, 59% in patients with inherited high cholesterol. On top of statins. That matches the injectable class in a daily tablet. But here's the detail that made me sit up as a cardiologist — the part most coverage is burying: enlicitide also significantly lowered ApoB and Lp(a). If you follow me, you know why that matters. Lp(a) is the genetic, inherited cholesterol particle that roughly one in five people carry at dangerous levels — the one that triples heart attack risk and that diet, exercise, and even statins barely touch. We've had almost nothing oral that moves it. A daily pill that lowers LDL, ApoB, AND Lp(a) simultaneously is a genuinely meaningful expansion of what we can do. Who should pay attention today: Anyone above their LDL goal despite maximum statins or ezetimibe. The roughly 9.8 million high-risk Americans still not at target. Anyone with familial hypercholesterolemia — the genetic condition that loads dangerously high LDL from birth and causes heart attacks in the 40s and 50s. These patients have avoided the injectables for years. Statin-intolerant patients who need powerful additional lowering. Anyone who's had a heart attack or stroke and needs to drive LDL far lower than a statin alone can manage. The price is notable too: about $315 a month, meaningfully below the injectables — though it'll still require insurance prior authorization, and formulary placement isn't set yet, so access won't be instant. Now the honest caveats, because I'm a physician, not a hype man: This approval is based on LDL lowering, not yet on proven outcomes. The big cardiovascular outcomes trial — CORALreef Outcomes, over 14,500 patients — is still running. We expect the heart-attack reduction to follow the LDL drop, because the link between lower LDL and fewer events is one of the most rock-solid relationships in all of medicine. But the definitive proof isn't in yet, and I'll tell you that honestly. And a pill isn't automatically right for everyone. Some patients love a shot they take twice a month and never think about again. This is a powerful new tool, not a mandate. But make no mistake about the size of this. For twenty years I've told patients that LDL is one of the most important numbers they will ever own — and that for the right person, lower is better, and lower earlier is better still. Today the tool to get there stopped requiring a needle. The medicine to protect your heart just got radically easier to take. And easier medicine is medicine people actually use. If you're on a statin and still not at goal — or high cholesterol runs in your family and you've been dodging the shots — this is the week to call your doctor and ask one question: "Is the new oral PCSK9 inhibitor right for me?" The needle was the wall. Today the wall came down. Know your numbers. The science to change them keeps winning.

I don’t need to hire a big team to run everything I do. I’m literally a one-man team, and Grok is a huge reason why. Think about everything that normally goes into running an account as big as mine… researching stories, checking facts, watching what’s happening on 𝕏 in real time, brainstorming posts, writing, editing, creating graphics, making videos, building tools, organizing ideas, and handling all the little things that eat up your entire day. I can now do ALL of that myself with Grok. I use Grok 4.6 as my brain for research, analysis, writing, ideas, and working through bigger projects. It can search the web and 𝕏 in real time, which is huge for me bc so much of what I cover is happening by the minute. Then there’s Grok Imagine. I can create images, edit visuals, turn ideas into videos, use image and voice references, and generate video up to 1080p. Stuff that would have required a professional designer, editor, or a separate creative team, can now start with me typing what’s in my head. I also pay for SuperGrok Heavy, which gives me access to the most advanced Grok features. Build Mode will turn my idea into a working website, app, game, tool, or dashboard without me needing to be a programmer. And now the biggest one for me is Grok Bot @bot. Grok Bot basically lets me build my own AI team. I can create Bots, give them real jobs, message them like teammates, and have them work across apps and websites using their own computers. They can remember how I like things done and handle multi-step work instead of just answering a single prompt. Grok Bot is currently available in beta to SuperGrok Heavy subscribers fyi. So when I say I’m a one-man operation, I mean it. I don’t have a research department. I don’t have a writing team. I don’t have a graphics department. I don’t have a video team. I don’t have a software team. It’s just me + Grok. And that’s what I think people are still underestimating about AI. It’s going to let one person operate like an entire company. And Teslaconomics is becoming my real-world experiment in exactly that.

Despite being a “successful” founder, I really am poor at several things. These aren’t fake weaknesses that one would share in job interviews. They are things I genuinely stink at and wish I stunk less. I’m disorganized. I’m impulsive. I procrastinate. I’m highly distractible. I have trouble sticking to a timeline. So how have I had one 9-figure outcome & another hypergrowth startup, in spite of my deficiencies? 1. I embrace the cringe. I make audacious asks to customers. I’ll look like an idiot on social media. I’ll push through the discomfort of asking innumerable questions and keep going until I actually understand something. I’ll make an ass out of myself if it means getting more exposure for my business. 2. I’m a one-trick pony. And I don’t feel bad about it. There are a few things I’m world class at. Building organic distribution. Relationship building with execs. And telling a compelling story. I spend 90% of my time sharpening these tools while letting others around me cook in their zones of genius. 3. I’m like a kid. If there’s one thing I’m good at it’s honoring my 5-year-old self. I’m insatiably curious. I probably ask 100+ questions/day to employees, customers, and people in my network. I’m goofy and playful. I can be serious, but most of the time I’m not, because most of what we do in knowledge work, just isn’t that serious. You can find me shooting nerf darts across the office or building a Lego set in between calls. Why do I share all of this? Because first time founder Alex wanted to be great at everything and enjoy every part of building a business. And if he didn’t, he thought something was wrong with him. Nothing was wrong with him. He was exactly what he needed to be and where he needed to be. He just didn’t believe it yet.

I'm a little on Cassie Pritchard's side in that I don't actually like love claiming that I "am" a "woman" like what does that even mean... I feel it's more that I'd like to be a woman, even though there's no fact of the matter about who precisely is a woman...